12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CCX832: Development discontinued

ChemoCentryx disclosed in an SEC filing that it and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) will discontinue development of CCX832 and its 2 backup compounds. ChemoCentryx said the decision was based on unblinded data from a Phase I trial in 40 healthy volunteers evaluating single doses of 1, 3, 10, 30 and...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >